Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Abbvie Inc (ABBV)

Abbvie Inc (ABBV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 383,080,704
  • Shares Outstanding, K 1,767,385
  • Annual Sales, $ 56,334 M
  • Annual Income, $ 4,278 M
  • EBIT $ 9,034 M
  • EBITDA $ 17,420 M
  • 60-Month Beta 0.36
  • Price/Sales 6.44
  • Price/Cash Flow 14.86
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 28.72% (+0.69%)
  • Historical Volatility 25.44%
  • IV Percentile 81%
  • IV Rank 32.86%
  • IV High 51.27% on 04/08/25
  • IV Low 17.68% on 02/19/25
  • Expected Move (DTE 7) 4.94 (2.28%)
  • Put/Call Vol Ratio 0.63
  • Today's Volume 8,041
  • Volume Avg (30-Day) 51,061
  • Put/Call OI Ratio 1.07
  • Today's Open Interest 277,331
  • Open Int (30-Day) 285,911
  • Expected Range 211.24 to 221.12

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 28 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 3.20
  • Number of Estimates 5
  • High Estimate 3.35
  • Low Estimate 2.65
  • Prior Year 2.16
  • Growth Rate Est. (year over year) +48.15%

Price Performance

See More
Period Period Low Period High Performance
1-Month
214.27 +1.07%
on 01/16/26
237.04 -8.64%
on 01/07/26
-7.10 (-3.17%)
since 12/16/25
3-Month
211.69 +2.31%
on 11/03/25
239.29 -9.49%
on 11/13/25
-10.30 (-4.54%)
since 10/16/25
52-Week
164.39 +31.74%
on 04/09/25
244.81 -11.54%
on 10/01/25
+42.87 (+24.68%)
since 01/16/25

Most Recent Stories

More News
AbbVie and Trump Administration Reach Agreement to Improve Access and Affordability for Americans

NORTH CHICAGO, Ill. , Jan. 12, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced a voluntary agreement with the Trump administration to further advance access and affordability for Americans...

ABBV : 214.98 (-0.02%)
AbbVie and RemeGen Announce Exclusive Licensing Agreement to Develop A Novel Bispecific Antibody for Advanced Solid Tumors

-       RC148 is a novel PD-1/VEGF bispecific antibody being evaluated in multiple advanced solid tumors including certain lung cancers

ABBV : 214.98 (-0.02%)
West Signs Agreement to Sell the Manufacturing and Supply Rights for SmartDose® 3.5mL On-Body Delivery System to AbbVie

EXTON, Pa. , Jan. 12, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that the company...

WST : 263.28 (-5.77%)
ABBV : 214.98 (-0.02%)
AbbVie to Acquire Arizona Manufacturing Facility, Further Strengthening Manufacturing Capabilities in the United States

NORTH CHICAGO, Ill. , Jan. 12, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) and West Pharmaceutical Services (NYSE: WST) announced today a definitive agreement for AbbVie to acquire a device manufacturing...

WST : 263.28 (-5.77%)
ABBV : 214.98 (-0.02%)
This ETF Is Proof That the Healthcare Rebound Is Real

Track healthcare’s 2026 setup: GLP-1 drug adoption, a valuation gap vs. tech, and why VHT offers broad exposure with low fees and dividends.

CVS : 79.45 (-2.35%)
VHT : 291.00 (-0.33%)
NVO : 61.69 (+8.00%)
JNJ : 219.55 (-0.01%)
MRK : 108.92 (-1.85%)
HCA : 473.26 (-2.18%)
ABBV : 214.98 (-0.02%)
UNH : 333.45 (-1.63%)
ELV : 375.54 (-1.67%)
PFE : 25.63 (-1.00%)
TSLA : 439.40 (+0.19%)
LLY : 1,045.59 (+1.22%)
December Jobs Report Miss Forecasts While Unemployment Defies Expectations

March S&P 500 E-Mini futures (ESH26) are trending up +0.33% this morning as investors digest the December U.S. payrolls report.

ADSK : 264.40 (+0.82%)
DDOG : 120.29 (-0.47%)
ASML.NA : 1,167.200 (+1.55%)
MU : 353.82 (+5.11%)
HII : 424.98 (+1.46%)
ABBV : 214.98 (-0.02%)
ESH26 : 6,985.75 (+0.06%)
TSM : 343.55 (+0.56%)
AVAV : 396.52 (+4.74%)
QCOM : 160.67 (-0.45%)
STX : 323.31 (+0.93%)
INTC : 46.84 (-3.06%)
Stocks Settle Mixed on Sector Rotation

The S&P 500 Index ($SPX ) (SPY ) on Thursday closed up +0.01%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.55%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.57%. March E-mini...

SNDK : 404.78 (-1.09%)
DASH : 206.25 (-1.84%)
OXY : 42.74 (-1.00%)
FANG : 149.62 (-0.80%)
STX : 323.31 (+0.93%)
WDC : 219.46 (-1.19%)
AMD : 232.57 (+2.04%)
STZ : 156.86 (-1.19%)
SPY : 692.68 (+0.06%)
AA : 61.21 (-4.07%)
NOC : 663.03 (+1.29%)
GMED : 94.44 (+0.59%)
1 Unpopular Stock That Deserves a Second Chance and 2 We Question

1 Unpopular Stock That Deserves a Second Chance and 2 We Question

ONTF : 7.97 (-0.06%)
ZION : 59.78 (+0.45%)
ABBV : 214.98 (-0.02%)
Worried About a K-Shaped Economy? Buy This Top Dividend ETF for 2026.

SCHD looks well-positioned to outperform significantly if the economy turns south in 2026.

LMT : 579.21 (+0.23%)
KO : 70.63 (+0.21%)
SCHD : 28.89 (-0.48%)
PEP : 146.33 (-0.16%)
ABBV : 214.98 (-0.02%)
AMGN : 329.17 (-0.26%)
PFE : 25.63 (-1.00%)
BMY : 55.64 (-1.73%)
Ironwood Pharmaceuticals’ 2026 Guidance Shock Sparks a Major Re-Rating

Ironwood Pharmaceuticals rose 30% after a strategic price cut on Linzess unlocked higher revenue guidance and surprised Wall Street analysts.

IRWD : 4.68 (+3.54%)
ABBV : 214.98 (-0.02%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi...

See More

Key Turning Points

3rd Resistance Point 228.44
2nd Resistance Point 225.74
1st Resistance Point 221.24
Last Price 214.98
1st Support Level 214.04
2nd Support Level 211.34
3rd Support Level 206.84

See More

52-Week High 244.81
Last Price 214.98
Fibonacci 61.8% 214.09
Fibonacci 50% 204.60
Fibonacci 38.2% 195.11
52-Week Low 164.39

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar